Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated

miscellaneous news
By:
On:

Amman, Jordan Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual General Meeting. Riad Mishlawi, Hikma’s CEO, said: “Hikma has had a strong start to 2024, with continued growth and momentum across the Group. Our three businesses are performingContinue Reading

Hikma continues strong momentum across the Group and upgrades guidance for 2023

Health and Beauty1
By:
On:

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Riad Mishlawi, Chief Executive Officer of Hikma, said: “The good momentum during the first half has continued, enabling us to upgrade full year guidance in two of our three businesses.Continue Reading

Hikma delivers strong H1 performance and raises Generics guidance Growth in all three businesses and across all geographies

Community
By:
On:

Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, report its interim results for the six months ended 30 June 2023. During the first half of 2023, core group revenue grew 18% to $1.427 billion (compared to H1 2022: $1.213 billion), driven by a strong performanceContinue Reading